Viralytics Receives Approval To Increase CAVATAK™ Dosage Levels In Intravenous Cancer Trial

News — By on April 20, 2009 at 2:00 am

Viralytics Limited (ASX: VLA) has received ethics committee approval to increase the dosage levels of CAVATAK™ in its Phase I intravenous breast cancer, prostate cancer and melanoma trial. Dosing will now commence at what was the highest dosing level of the original trial schedule and escalate to approximately 100 fold higher levels than planned for in the original design. The intravenous trial will now comprise nine patients in total.

Please read the complete article and let us know what you think below.

Leave a Reply


Leave a Trackback